INGREZZA Demonstrates Efficacy in Treating Tardive Dyskinesia
SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has announced impressive results from a recent study illustrating that nearly 60% of participants experienced remission of tardive dyskinesia after a 48-week treatment with INGREZZA (valbenazine) capsules. This revelation stems from the KINECT-4 study, a pivotal long-term clinical trial dedicated to addressing this debilitating movement disorder.
Understanding Tardive Dyskinesia and Study Details
Tardive dyskinesia (TD) manifests as involuntary, repetitive motions, often triggered by prolonged use of specific antipsychotic drugs. The KINECT-4 Phase 3 study involved 163 individuals with moderate to severe TD, who received INGREZZA for the entirety of the 48 weeks. The primary goal of the study was to evaluate changes in the Abnormal Involuntary Movement Scale (AIMS) score, a tool used to assess the severity of TD symptoms.
Study Outcomes and Remission Rates
The findings revealed that 59.2% of participants achieved a score of 1 or below on every AIMS item by Week 48, indicating a remission of symptoms. When looking at dosage, 65.0% of those on the 40 mg dose successfully reached remission compared to 57.8% in the 80 mg group. Notably, 10% of participants demonstrated complete resolution of symptoms with an AIMS total score of 0.
Safety and Tolerability Observations
In addition to evaluating efficacy, the study included thorough monitoring of INGREZZA’s safety and tolerability. Treatment-emergent adverse events (TEAEs) occurring in more than 5% of participants included headaches and urinary tract infections. Other parameters, such as psychiatric stability and vital signs, remained relatively stable and were not deemed clinically significant.
Delving into Recent Developments at Neurocrine
Recently, Neurocrine Biosciences shared more data at the 2024 Psych Congress in Boston, which included findings regarding INGREZZA's benefits for patients with dysphagia and improvements in their quality of life post-treatment. INGREZZA functions as a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, receiving FDA approval for use in adults suffering from tardive dyskinesia and chorea linked with Huntington's disease.
Financial Performance and Future Aspirations
Neurocrine Biosciences is gaining attention alongside notable positive news. The company’s recent earnings report for the third quarter of 2024 displayed substantial growth, with sales of INGREZZA reaching $613 million. This significant performance has led to an upward revision of their annual revenue guidance to between $2.3 and $2.32 billion, indicating a 25% increase compared to the previous year.
Market Predictions and Analyst Ratings
BMO Capital Markets has adjusted its price target for Neurocrine Biosciences from $114 to $121, maintaining a Market Perform rating based on encouraging third-quarter outcomes and expectations surrounding the potential FDA approval for crinecerfont, which targets congenital adrenal hyperplasia (CAH). This medication holds considerable promise with the potential to generate peak revenues around $600 million.
Investments in Growth and Innovation
CEO Kyle Gano revealed a strategic $300 million share repurchase plan, signifying the company’s commitment to nurturing revenue growth. Alongside this, Neurocrine is preparing for the rollout of Crinecerfont, aiming at pediatric and community endocrinology practices, thus broadening its market outreach.
Research and Future Prospects
Neurocrine is actively investing in novel research and development initiatives, progressing its pipeline with Phase III trials for NBI-845 and NBI-568 expected in 2025. This steady evolution highlights the company's dedication to expanding their therapeutic offerings.
Frequently Asked Questions
What is INGREZZA used for?
INGREZZA is a medication used to treat tardive dyskinesia and chorea associated with Huntington’s disease.
What were the remission rates observed in the KINECT-4 study?
The study found that approximately 59.2% of participants achieved remission after 48 weeks of treatment.
What percentage of participants achieved complete resolution of symptoms?
10% of participants demonstrated a complete resolution of tardive dyskinesia symptoms with a total AIMS score of 0.
How has Neurocrine's financial performance been recently?
Neurocrine reported strong growth, with INGREZZA sales reaching $613 million, and raised its annual revenue guidance significantly.
What future developments are expected from Neurocrine?
Neurocrine is anticipating launching new treatments such as crinecerfont and advancing its research pipeline with upcoming studies.
